cvs health glp-1 receptor agonists weight management diabetes treatments Cardiovascular Protective Properties of Agonists: More than Just Diabetic and Loss Drugs GLP-1 Resource Center

doi: 10.1136/bmj.l4898 7 TanZHuangSMeiKLiuMMaJJiangYet al

The Effect of Liraglutide on Weight Loss in Women With Polycystic Ovary Syndrome: An Observational Study

Eligible participants had CKD defined as either an eGFR of 5075 mL/min/1.73 m 2 with UACR 3005,000 mg/g, or an eGFR of 25 to 50% eGFR decline, ESKD, or all-cause mortality [81]

H., Anefors C., Bergquist F., Nissbrandt H., Skibicka K

Originally designed to treat type 2 diabetes, these medications have shown remarkable success in promoting weight loss by regulating appetite and improving blood sugar control

A similar impact on biomarkers of liver damage has also been demonstrated for lixisenatide [75], dulaglutide [78,79], liraglutide [73,76,77] and semaglutide [61,80]